Parkinson's disease is the second most common neurodegenerative disorder 1,2 . Growing evidence indicates a causative role of misfolded forms of the protein a-synuclein in the pathogenesis of Parkinson's disease 3, 4 . Intraneuronal aggregates of a-synuclein occur in Lewy bodies and Lewy neurites 5 , the cytopathological hallmarks of Parkinson's disease and related disorders called synucleinopathies 4 . a-Synuclein has long been defined as a 'natively unfolded' monomer of about 14 kDa (ref. 6) that is believed to acquire a-helical secondary structure only upon binding to lipid vesicles 7 . This concept derives from the widespread use of recombinant bacterial expression protocols for in vitro studies, and of overexpression, sample heating and/or denaturing gels for cell culture and tissue studies. In contrast, we report that endogenous a-synuclein isolated and analysed under non-denaturing conditions from neuronal and non-neuronal cell lines, brain tissue and living human cells occurs in large part as a folded tetramer of about 58 kDa. Several methods, including analytical ultracentrifugation, scanning transmission electron microscopy and in vitro cell crosslinking confirmed the occurrence of the tetramer. Native, cell-derived a-synuclein showed a-helical structure without lipid addition and had much greater lipid-binding capacity than the recombinant a-synuclein studied heretofore. Whereas recombinantly expressed monomers readily aggregated into amyloid-like fibrils in vitro, native human tetramers underwent little or no amyloid-like aggregation. On the basis of these findings, we propose that destabilization of the helically folded tetramer precedes a-synuclein misfolding and aggregation in Parkinson's disease and other human synucleinopathies, and that small molecules that stabilize the physiological tetramer could reduce a-synuclein pathogenicity.
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To identify the native state of a-synuclein in cells while avoiding the potential breakdown of physiological assemblies by detergents, we initially used native gel electrophoresis. a-Synuclein is expressed endogenously in many cell types, so we chose to analyse the dopaminergic human neuroblastoma line, M17D (ref. 8) and the commonly used cell lines HEK293, HeLa and COS-7. Each of these cell lines predominantly contained a non-denatured a-synuclein-immunoreactive species migrating in blue native-polyacrylamide gel electrophoresis (BN-PAGE) at ,45-50 kDa (Fig. 1a , lanes 1-4). Because these initial results suggested an apparently stable oligomeric form under native conditions, we next probed the endogenous state of a-synuclein in normal brain. The frontal cortex of wild-type mice also revealed a ,45-50 kDa form of endogenous a-synuclein as the main species in the buffersoluble fraction (Fig. 1a, lane 6) .
To assess the state of endogenous a-synuclein in living human cells, we examined freshly collected red blood cells (RBCs), which were recently found to have high a-synuclein expression 9 . Human RBCs contained a ,45-50 kDa a-synuclein immunoreactive band on BN-PAGE (Fig. 1a, lane 5) . As a second non-denaturing gel system that precludes effects of the Coomassie dye used in BN-PAGE, we performed clear native-PAGE (CN-PAGE) 10 . The main a-synuclein species in all samples migrated at ,55-60 kDa, suggesting a tetramer (theoretical mass of monomer 5 14,460 Da) ( Fig. 1b, lanes 1-6) . The better resolution of CN-PAGE without Coomassie dye also revealed small amounts of apparent monomers running below the 14 kDa molecular weight marker (Fig. 1b, lanes 1-4, 6 ) and distinguished the small differences in amino acid length of the human and mouse a-synuclein monomers and putative tetramers (Fig. 1b, lane 6) . The endogenous ,55-60 kDa species was detected by monoclonal asynuclein antibodies Syn1, Syn211 and LB509 and polyclonal antibody C20 in both native gel systems.
Because the migration of a protein on BN-or CN-PAGE does not depend solely on its mass but also on its conformation and charge, we used in vitro crosslinking to preserve the assembled state of the putative a-synuclein oligomer, followed by denaturing SDS-PAGE. We observed SDS-stable a-synuclein bands migrating at the expected positions of a tetramer (,55 kDa) and non-crosslinked monomer in all cells, plus some putative dimer in the HeLa, HEK and red blood cells (right panel of Fig. 1c ). This in vivo crosslinking supports the existence of native tetramers in cells. We performed two-dimensional gel analysis after the in vivo crosslinking; that is, isoelectric focusing (IEF) to separate proteins by charge in a pH gradient followed by denaturing SDS-PAGE. The higher-migrating a-synuclein species in the crosslinked RBC lysates had the same pK a as monomers, within the limits of IEF resolution ( Supplementary Fig. 1 ), consistent with their being homo-oligomers. Next, we developed a non-denaturing method to purify native a-synuclein from soluble RBC lysates (see Methods and Nature Protocol Exchange (http://www.nature.com/protocolexchange/protocols/2136)). This allowed us to estimate the mass of native a-synuclein based on distinct measurement principles that are not affected by protein conformation, unlike gel electrophoresis. Scanning transmission electron microscopy (STEM) is useful for measuring the masses of purified, non-covalently bonded complexes that may not resist ionization during mass spectrometry 11, 12 . STEM images of a-synuclein purified under non-denaturing conditions from human RBCs ( Supplementary Fig. 2 ) yielded a homogenous distribution of roughly spherical particles measuring ,3.0-3.5 nm in diameter ( Fig. 2a ). Unbiased automatic sampling of 1,000 particles gave a size distribution pattern with a peak at ,55 kDa ( Fig. 2b ). Importantly, we next applied sedimentation equilibrium analytical ultracentrifugation (SE-AUC), a technique commonly used to establish the oligomeric state of native proteins independent of their conformation. SE-AUC analysis of purified, native RBC a-synuclein performed at three different concentrations and at different rotor speeds yielded an average molecular weight of 57.8 kDa (4.78 Svedbergs), strongly supporting a tetrameric assembly state ( Fig. 2c ).
Numerous studies have reported conformational changes in a-synuclein, with a focus on the natively unfolded recombinant monomer undergoing a random coil to a-helix transition upon in vitro interaction with small lipid vesicles 7 . This change is believed to be relevant to the poorly defined physiological function of a-synuclein in cells and could potentially decrease the likelihood of its aggregation into b-sheet-rich neurotoxic assemblies 13 . Unexpectedly, we found that circular dichroism spectra of the human RBC tetramer purified under non-denaturing conditions showed two minima of mean residue ellipticity at 222 and 208 nm ( Fig. 3a) , characteristic of an a-helically folded protein 14 . This result is inconsistent with the common assumption that a-synuclein is natively unfolded. The addition of negatively charged, small unilamellar lipid vesicles (SUVs) did not induce a significant conformational change in the native tetramer by circular dichroism (Fig. 3a) , but a random coil to a-helical conversion did occur (as reported) with recombinant monomer that had been expressed in bacteria (Fig. 3b ). Incubation of the purified RBC a-synuclein tetramer with Lipidex 1000, a reagent used to strip proteins of bound lipids and fatty acids 15 , did not change the conformation of the a-helical a-synuclein tetramer ( Supplementary Fig. 3 ), suggesting that significant lipid association is not required to maintain the folded structure of cellular a-synuclein. To support this possibility, we conducted a quantitative elemental phosphate analysis 16 on the purified native a-synuclein to search for phospholipid. We obtained an average value of 0.25 mol phosphate per mol a-synuclein, making a significant presence of phospholipids on the a-helical a-synuclein purified from normal cells unlikely. Because post-translational modifications also could have an impact on the conformational differences between the native human RBC tetramer and the bacterially expressed, recombinant human monomer, we performed mass spectrometry. The recombinant protein showed a mass peak at 14,462 kDa, very close to the theoretical predicted mass of 14,460 kDa, whereas the purified erythrocyte a-synuclein showed a peak at 14,505 kDa, indicative of only an N-a-acetylation commonly present on human proteins (theoretical predicted mass 5 14,502 kDa) ( Supplementary Fig. 4) .
To validate the above results obtained on RBC a-synuclein using a different human cell type and a different non-denaturing purification method, we isolated a-synuclein from a M17D human neuroblastoma cell line stably overexpressing wild-type human a-synuclein (3D5 cells 17 ). a-Synuclein from untransfected M17D cell lysates migrated above bacterially expressed a-synuclein of confirmed random coil structure on CN-PAGE ( Supplementary Fig. 5A ). This higher electrophoretic migration was also true of native (a-helical) but not RESEARCH LETTER denatured (random coil) purified RBC a-synuclein ( Supplementary  Fig. 5B ). After a-synuclein was purified from the stably transfected 3D5 cell line or from RBCs, the two differentially purified and ahelically folded (by circular dichroism) cellular proteins co-migrated at ,55-60 kDa on CN-PAGE, as expected ( Supplementary Fig. 6 ). Unbiased, automated STEM measurements of 3,000 particles revealed that the 3D5 neuroblastoma cells contained a-synuclein tetramers of closely similar estimated molecular weight (peak mass ,55 kDa) to those of the RBC a-synuclein ( Supplementary Fig. 7 ; compare to Fig. 2b ). Circular dichroism spectroscopy revealed the purified 3D5 cell a-synuclein to have two minima of mean residue ellipticity at 222 and 208 nm ( Supplementary Fig. 8 ). To further exclude artefacts arising during purification of cellular a-synuclein such as adventitious association of biomolecules (for example, cellular lipids not removed by Lipidex 1000) that artificially fold the protein, we repeated our experiments with the 3D5 parental line M17D, which has only low levels of endogenous a-synuclein. We added ('spiked') bacterially expressed recombinant human monomer onto the M17D cells before performing cell lysis and the full purification, and then assayed its structural properties. This exposure to cell lysates and the purification procedure led to no induction of helical folding in the recombinant human a-synuclein ( Supplementary Fig. 9 ), whereas simultaneously purified 3D5 cell human a-synuclein did show this conformation, supporting our conclusion that a-helically folded a-synuclein does not arise owing to artificial manipulation of the protein.
Membrane association has been viewed as a principal functional property of a-synuclein in vitro 7 and in living cells 18 . We searched for differential binding of recombinant monomeric human a-synuclein versus RBC tetrameric human a-synuclein to a lipid membrane using surface plasmon resonance (SPR). Because recombinant a-synuclein is reported to have preferential affinity for negatively charged lipids, especially phosphatidyl serine 7 , we chose a mixed phosphatidyl choline and phosphatidyl serine (PC/PS) membrane as a model membrane. Exposure of a PC/PS membrane to cell-derived, purified native a-synuclein in a Biacore instrument produced a markedly increased resonance angle shift compared to conventional recombinant monomers at identical concentrations in solution (Fig. 3c) , indicating dramatically increased lipid binding. Fitting a dilution series of a-synuclein tetramer injections to a two-state binding model ( Supplementary Fig. 10 ) gave an apparent dissociation constant of K app 5 56 6 61 nM, which is about two orders of magnitude lower than values obtained for recombinant monomer in analogous SPR studies 19 . We next tested the amyloid aggregation propensity of the distinct species in a Thioflavin T (ThT) fluorescence assay. Monomeric and tetrameric a-synuclein showed very different characteristics, with samples of purified cellular a-synuclein incubated under identical conditions showing no evidence of fibril formation in a time (10 days) more than sufficient to form mature, ThT-bound fibrils from equivalent amounts of unfolded recombinant a-synuclein (Fig. 3d ). Analysis of protein concentration in the solution after the 10-day incubation showed that the RBC a-synuclein was still present and soluble, making non-amyloid (that is, ThT-negative) aggregation of the tetramers unlikely. Interestingly, melting curves of purified tetrameric a-synuclein showed that heat denaturation (at 95 uC) seemed irreversible under our conditions ( Supplementary Fig. 11) .
Our experiments provide several independent lines of evidence that endogenous cellular a-synuclein exists in large part as an a-helically folded, ,58 kDa tetramer under native conditions. This finding is in contrast to many biophysical and biochemical studies describing a-synuclein as a natively unfolded ,14 kDa monomer. In an early study of bacterially expressed recombinant protein purified under non-denaturing conditions or with heat treatment, no conformational differences were observed, and it was concluded that a-synuclein is a natively unfolded monomer 6 . This suggests problems in generating properly folded protein in Escherichia coli, although a modified bacterial expression protocol avoiding heating and denaturants has recently been found to yield a helical a-synuclein tetramer closely resembling the species found by us in native human samples (W. Wang et al., personal communication). The reasons for the conformational differences observed in these two bacterial studies are unknown. Using gel filtration on unfolded recombinant a-synuclein also showed an apparent molecular weight of ,60 kDa in some earlier studies; the data were interpreted as a decrease in mobility of the extended state of an unfolded protein in the tested matrices 6 . This suggests the possibility 
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of a similar hydrodynamic radius for the unfolded monomer and the more compact, helically folded tetramer, making gel filtration an unreliable indicator (and therefore not used here). Our evidence for a tetrameric molecular mass of endogenous a-synuclein was particularly supported by the analytical ultracentrifugation and the unbiased STEM analysis, both of which sizing methods are not based on conformation. The STEM sizing was performed on intrinsic a-synuclein isolated from two cell types and using two distinct non-denaturing procedures.
Our apparent disagreement with most published findings on the monomeric state of a-synuclein in cells and brain tissue, usually as judged by SDS-PAGE and western blotting, can be explained by the common use of denaturing detergents. Our tetramer aggregation data (Fig. 3d ) are consistent with a recent report describing non-neurotoxic, aggregation-resistant a-synuclein oligomers in vivo 20 . Moreover, an oligomeric species of a-synuclein (size undefined) was observed by in vivo fluorescence lifetime imaging in an intact cell culture model 21 .
Given the close match between our observed molecular weights using SE-AUC ( Fig. 2c) and STEM ( Fig. 2b and Supplementary Fig. 7 ) and the theoretical weight of a tetramer, the detection of a tetrameric band on denaturing gels after in vivo crosslinking (Fig. 1c) , and the IEF evidence post-crosslinking that the endogenous tetramer and dimer bands have pK a values similar to that of a monomer ( Supplementary  Fig. 1 ), we conclude that the predominant physiological species of a-synuclein in cells and brain is a helically folded tetramer, although minor and variable amounts of monomers, dimers and trimers were detected in some cell types. The closely similar properties of a-synuclein observed until now in neural cells and fresh human RBCs recommends the latter as an abundant, available source for future studies of physiological a-synuclein.
The higher lipid-binding capacity of native a-synuclein leads us to speculate that the monomer represents a not fully functional and less abundant species in normal cells. Given the much lower propensity of the native tetramer to aggregate into fibrils (Fig. 3d) , it is likely that tetramers undergo destabilization before a-synuclein aggregates into abnormal oligomeric and fibrillar assemblies that can confer cytotoxicity in Parkinson's disease and other a-synucleinopathies. Hypothetically, such a mechanism could be analogous in part to transthyretin amyloidosis, in which a native metastable tetramer circulates in human plasma but can become destabilized (for example, by pathogenic missense mutations) to allow monomers to aggregate aberrantly in tissue 22 . Our identification of helically folded a-synuclein tetramers encourages the design of compounds that, like those for transthyretin 23 , could kinetically stabilize native tetramers and prevent pathogenic a-synuclein aggregation as a novel treatment approach for Parkinson's disease, dementia with Lewy bodies and other synucleinopathies 24 .
METHODS SUMMARY
Native gel electrophoresis was conducted as described 10 . For crosslinking, 1-5 mM disuccinimidyl suberate was added to living cells. RBC lysates were treated analogously but using 1 mM bis(sulphosuccinimidyl) suberate. To purify a-synuclein from fresh or packed frozen RBCs, an initial 25% (NH 4 ) 2 SO 4 cut followed by a 50% (NH 4 ) 2 SO 4 precipitation substantially enriched a-synuclein. The resolubilized 50% pellet was injected onto a hydrophobic interaction column (HiTrap Phenyl HP; GE Healthcare) and eluted in 1 M to 0 M (NH 4 ) 2 SO 4 , pH 7. Alternatively, a-synucleinoverexpressing 3D5 neuroblastoma cell lysate after (NH 4 ) 2 SO 4 was injected onto a 5-ml HiTrap Q HP column. A 25-500 mM NaCl (pH 8.0) gradient eluted a-synuclein at ,300 mM NaCl. a-Synuclein from both cell sources underwent a final purification step on a Superdex 75 SEC column. STEM analysis was conducted at the Brookhaven National Laboratory STEM user facility. Sedimentation equilibrium data were acquired on a Beckman XL-I analytical ultracentrifuge at speeds of 11,612, 20,644 and 32,256g (AN-60 Ti rotor) and protein concentrations of 0.6, 1.1 and 1.6 mg ml 21 . Circular dichroism spectroscopy for lipid-induced a-synuclein folding was conducted in the presence of 4 mM PC/PS (4:1) SUVs. SPR spectroscopy was conducted as described 19 . To quantify amyloid fibril growth, aliquots (10 ml) of purified a-synuclein were added to a 10 mM ThT solution in 10 mM glycine buffer, pH 9. ThT fluorescence was measured by exciting at 444 nm and scanning the emission wavelengths from 460-550 nm.
